A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
|ClinicalTrials.gov Identifier: NCT00001339|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : March 4, 2008
Patients who have no response to preoperative chemotherapy and no residual disease following surgery on Regimen A are treated on Regimen B postoperatively.
The following acronyms are used:
DDD Mitotane, NSC-38721
DOX Doxorubicin, NSC-123127
VCR Vincristine, NSC-67574
VP-16 Etoposide, NSC-141540
Regimen A: 4-Drug Combination Chemotherapy followed by Surgery followed by 4-Drug Combination Chemotherapy. DDD/DOX/VCR/VP-16; followed by surgical debulking; followed by DDD/DOX/VCR/VP-16.
Regimen B: Single-Agent Chemotherapy. DDD.
|Condition or disease||Intervention/treatment||Phase|
|Adrenal Cortical Carcinoma||Drug: doxorubicin, vincristine, and etoposide with mitotane||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||42 participants|
|Official Title:||A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection|
|Study Start Date :||August 1993|
|Study Completion Date :||August 2002|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001339
|United States, Maryland|
|National Cancer Institute (NCI)|
|Bethesda, Maryland, United States, 20892|